tiprankstipranks
Glanbia Plc (GLAPF)
OTHER OTC:GLAPF
US Market

Glanbia (GLAPF) Earnings Dates, Call Summary & Reports

Compare
39 Followers

Earnings Data

Report Date
Aug 19, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
Last Year’s EPS
0.63
Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 25, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call presents a balanced picture: robust top-line growth, strong cash generation, active shareholder returns, and clear strategic progress (notably in Health & Nutrition, Optimum Nutrition momentum, M&A and capacity expansion). These positives are materially offset by significant margin pressure in Performance Nutrition driven by record whey input costs, a marked decline in PN EBITDA, sizeable exceptional charges related to transformation and disposals, and near-term cost/price lags that will affect 2026 results. Management has contracts in place for whey supply, is implementing further pricing, and expects margin recovery over the medium term supported by the transformation savings and capacity investments, but near-term execution and elevated input costs keep the outlook mixed.
Company Guidance
The company guided to 2026 and medium‑term targets that include: Performance Nutrition like‑for‑like organic revenue growth of 5–7% in 2026 (pricing‑led) and a target to improve PN EBITDA margins by 250 basis points by 2028; Health & Nutrition revenue growth of 4–6% in 2026 with H&N EBITDA margins targeted at 17–19%; Dairy Nutrition EBITDA expected at $150–160m; adjusted EPS growth of 7–11% (medium term and reiterated for 2026) with operating cash conversion above 85% (2025 conversion was 91%), return on capital employed of 10–13% (2025 ROCE 11.3%), and a dividend payout ratio target of 30–40% (2025 total dividend €0.4287/share; payout 35.9%). Near‑term financials and capital allocation: 2026 capex $100–110m (including ~$40m of capacity projects to be substantially completed by end‑2026), authorized further €100m share buyback (initial €50m tranche), returned €197m via buybacks in 2025 (15m shares at €13.10 avg), returned €102.5m in dividends in 2025, 2025 adjusted EPS $1.3493 (ahead of prior $1.30–1.33 guide), 2025 pre‑exceptional EBITDA $499.1m (down 9.4% cc), free cash flow $360m, operating cash flow ~$454m, net debt $526m (net debt/EBITDA 1.08x), interest cover 13.7x, and $1.4bn committed facilities (WAM 2.7 years). Key commodity and program assumptions: whey costs are expected to remain elevated with a double‑digit year‑on‑year increase assumed for 2026 (supply contracted into early Q4), new global whey supply of ~15–20% starting to come on stream in 2026, and the transformation program is expected to deliver $60m annual savings by 2027 (40% realized in 2026; ~50% of savings to be reinvested).
Revenue and Volume Growth
Group revenue of $3.95 billion, up 2.3% on a constant currency basis; group volumes up 3.7% and price up 0.5%.
Adjusted EPS Beat and Guidance Outperformance
Adjusted EPS of $1.3493, down 2.4% constant currency year-on-year but ahead of the prior guidance range of $1.30–$1.33.
Strong Cash Generation and Balance Sheet Metrics
Operating cash flow of just over $454 million with operating cash conversion of 91% (target 80%); free cash flow of $360 million; net debt of $526 million (net debt/EBITDA 1.08x) and interest cover 13.7x; $1.4 billion committed facilities.
Shareholder Returns and Capital Allocation
Returned ~EUR 197 million via share buybacks (15 million shares at average EUR 13.10); Board authorized an additional EUR 100 million buyback and commenced an initial EUR 50 million tranche; increased final dividend by 10% to a total EUR 0.4287 per share (payout ratio 35.9%).
Health & Nutrition Outperformance
Health & Nutrition delivered like-for-like revenue growth of 6.8% (volume +7.4%, price -0.6%); total revenue +11.5% including acquisitions; H&N EBITDA $115.8 million, up 16.7% constant currency; EBITDA margin improved to 18.4% (+80 bps).
Performance Nutrition Top-line Momentum and Brand Strength
Performance Nutrition like-for-like revenue +4.5% excluding noncore brands; Optimum Nutrition (ON) like-for-like revenue +6.4% (volume +5%, price +1.4%) with double-digit like-for-like revenue growth in H2 and strong online and international performance.
Dairy Nutrition Solid Volume Growth
Dairy Nutrition like-for-like revenue +5% (volume +4.2%, price +0.8%); continued demand for whey and protein solutions and momentum in new protein solution wins.
Strategic M&A, Capacity Expansion and Transformation
Acquisitions completed (Sweetmix; Scicore completed post year-end), approved capacity expansions (spray drying in U.S., doubling Asian premix capacity), and a group transformation program targeting at least $60 million annual cost savings by 2027 (~40% expected in 2026).
Medium-Term Growth Targets and Guidance
Medium-term targets reiterated: PN organic growth 5–7% p.a., H&N 4–6% p.a.; PN EBITDA margin uplift target of 250 bps by 2028; group EPS growth target 7–11% p.a.; 2026 outlook: PN like-for-like revenue growth 5–7% and H&N revenue growth 4–6%.

Glanbia (GLAPF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GLAPF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 19, 2026
2026 (Q2)
- / -
0.63
Feb 25, 2026
2025 (Q4)
0.70 / 0.72
0.7180.14% (<+0.01)
Aug 13, 2025
2025 (Q2)
0.57 / 0.63
0.682-7.62% (-0.05)
Feb 26, 2025
2024 (Q4)
0.70 / 0.72
0.5823.79% (+0.14)
Aug 14, 2024
2024 (Q2)
0.67 / 0.68
0.60812.17% (+0.07)
Feb 28, 2024
2023 (Q4)
- / 0.58
0.5525.07% (+0.03)
Aug 16, 2023
2023 (Q2)
0.57 / 0.61
0.53214.29% (+0.08)
Mar 01, 2023
2022 (Q4)
- / 0.55
0.37945.65% (+0.17)
Nov 03, 2022
2022 (Q3)
- / -
0.611
Aug 17, 2022
2022 (Q2)
- / 0.53
0.62-14.19% (-0.09)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GLAPF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 25, 2026
$19.46$20.11+3.34%
Aug 13, 2025
$13.82$13.820.00%
Feb 26, 2025
$13.96$13.960.00%
Aug 14, 2024
$18.86$17.48-7.30%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Glanbia Plc (GLAPF) report earnings?
Glanbia Plc (GLAPF) is schdueled to report earning on Aug 19, 2026, Before Open (Confirmed).
    What is Glanbia Plc (GLAPF) earnings time?
    Glanbia Plc (GLAPF) earnings time is at Aug 19, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is GLAPF EPS forecast?
          Currently, no data Available